In South Korea, conversations with strangers traditionally begin by sharing one’s age, which helps determine the proper use ...

In South Korea, conversations with strangers traditionally begin by sharing one's age, which helps determine the proper use ...

South Korea has experienced its first rise in birthrate in nearly a decade, with 242,334 babies born in 2024, a 3.1% increase from the previous year, according to the Ministry of the Interior and ...

The East Asian country posted 240,000 births last year, according to preliminary estimates, boosting the country's fertility rate to 0.75 from 0.72 in 2023. A fertility rate of 2.1 births expected per ...

Supported by operational growth of 6.7%, Johnson & Johnson (JNJ, Financials) reported a 5.3% rise in fourth-quarter revenues to $22.5 billion. With operational growth of 5.9% except for COVID-19 ...

Johnson & Johnson (JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share. Several negative impacts were highlighted in the ...

In a move that could redefine decades of US foreign policy, President Donald Trump casually referred to North Korea as a “nuclear power” during an impromptu Oval Office exchange with reporters ...

Control of Korea Zinc, the world’s largest producer of zinc, is at stake in a battle challenging the country’s entrenched chaebol system of powerful conglomerates. By Daisuke Wakabayashi and ...

A key member of impeached South Korean President Yoon Suk Yeol’s political party was in Washington this week calling on President Trump to express support for freedom and democracy in Northeast ...

The country said North Korea can “never be recognized as a nuclear-armed state,” NBC News reported. President Donald Trump, left, meets with North Korean leader Kim Jong Un at the North Korean ...

Johnson & Johnson (NYSE:JNJ) is scheduled to announce Q4 earnings results on Wednesday, January 22nd, before market open. Analysts expect a profit per share of $2.02, which is a decline of 11.8% ...

Also Read: Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal This approval, granted following FDA Priority Review ...